Frankfurt - Delayed Quote EUR

Microbot Medical Inc. (CY9D.F)

2.1460
+0.0260
+(1.23%)
As of 8:16:23 AM GMT+2. Market Open.
Loading Chart for CY9D.F
  • Previous Close 2.1200
  • Open 2.1460
  • Bid 2.1080 x --
  • Ask 2.1940 x --
  • Day's Range 2.1460 - 2.1460
  • 52 Week Range 0.7000 - 3.7000
  • Volume 1,315
  • Avg. Volume 90
  • Market Cap (intraday) 80.768M
  • Beta (5Y Monthly) 1.15
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6500
  • Earnings Date May 16, 2025 - May 22, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

microbotmedical.com

20

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CY9D.F

View More

Performance Overview: CY9D.F

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CY9D.F
78.83%
S&P 500 (^GSPC)
0.19%

1-Year Return

CY9D.F
149.68%
S&P 500 (^GSPC)
11.01%

3-Year Return

CY9D.F
52.64%
S&P 500 (^GSPC)
46.44%

5-Year Return

CY9D.F
65.11%
S&P 500 (^GSPC)
105.77%

Compare To: CY9D.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CY9D.F

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    79.79M

  • Enterprise Value

    75.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    24.37

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -101.21%

  • Return on Equity (ttm)

    -284.97%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.44M

  • Diluted EPS (ttm)

    -0.6500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.47M

  • Total Debt/Equity (mrq)

    3.14%

  • Levered Free Cash Flow (ttm)

    -5.87M

Research Analysis: CY9D.F

View More

Company Insights: CY9D.F

Research Reports: CY9D.F

View More